Allergan Adapts Trial Design; Latisse Endpoints Based On Consumer Feedback
Executive Summary
The clinical trial endpoints for Allergan's eyelash stimulant drug, Latisse, were determined through discussions with consumer panels about what was most desired in a drug that enhances eyelashes